GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 14 Mar 2013.
Leucine-rich repeat kinase 2
LRRK2, leucine-rich repeat kinase 2, PARK8
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008] (from
NCBI)
Sponsored links
Papers using
LRRK2
antibodies
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
Supplier
In PLoS ONE, 2009
... ReagentsAll cell culture media and supplements, BacMam LRRK2-GFP reagents, PrestoBlue™ cell viability assay reagent, Western blotting reagents and human neural stem cells were obtained from Life Technologies (Carlsbad, CA) ...
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Supplier
In PLoS ONE, 2009
... For LRRK2, rabbit monoclonal MJFF2 (Epitomics – see ...
Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors
Supplier
In International Journal of Biological Sciences, 2008
... LRRK2 and tTA transgenic rats were produced by ...
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.
Supplier
In PLoS ONE, 2007
... Full length WT-LRRK2 pCMV6-XL5 was purchased from Origene (NM_198578.2) ...
Tyramine and octopamine independently inhibit serotonin-stimulated aversive behaviors in Caenorhabditis elegans through two novel amine receptors.
more suppliersSupplier
In PLoS ONE, 2006
... driven WT or mutant LRRK2 constructs, were injected with the co-injection marker, promoter of nmr-1 driven YFP2 [55], into transgenic wild type nematode lines ...
Papers on
LRRK2
Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression.
New
Impact
Germany. In Cell Stem Cell, 07 Apr 2013
The LRRK2 mutation G2019S is the most common genetic cause of Parkinson's disease (PD).
Interplay of LRRK2 with chaperone-mediated autophagy.
New
New York City, United States. In Nat Neurosci, 03 Apr 2013
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease.
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
New
Lund, Sweden. In Parkinsonism Relat Disord, 22 Mar 2013
Mutations in seven genes are robustly associated with autosomal dominant (SNCA, LRRK2, EIF4G1, VPS35) or recessive (parkin/PARK2, PINK1, DJ1/PARK7) Parkinson's disease (PD) or parkinsonism.
The LRRK2 R1628P Variant Plays a Protective Role in Han Chinese Population with Alzheimer's Disease.
New
Shanghai, China. In Cns Neurosci Ther, 20 Mar 2013
Mutations within leucine-rich repeat kinase 2 (LRRK2) have been reported to be responsible for PD, and the location of LRRK2 is within a linkage peak for sporadic AD (SAD).
Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
New
San Francisco, United States. In Bioorg Med Chem Lett, 15 Mar 2013
Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial Parkinson's disease (PD).
Triazolopyridazine LRRK2 kinase inhibitors.
New
San Francisco, United States. In Bioorg Med Chem Lett, 14 Mar 2013
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD).
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
New
Impact
Beijing, China. In Nature, Dec 2012
We decided to evaluate nuclear organization in the context of ageing-associated disorders by focusing on a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S; glycine-to-serine substitution at amino acid 2019), which is associated with familial and sporadic Parkinson's disease as well as impairment of adult neurogenesis in mice.
Cellular reprogramming: a new approach to modelling Parkinson's disease.
Review
New
Oxford, United Kingdom. In Biochem Soc Trans, Oct 2012
In the case of PD (Parkinson's disease), reprogramming is advancing rapidly, and cell lines have been generated from patients carrying mutations in several disease-associated genes, including SNCA (α-synuclein), PARK2 (parkin), PINK1 (phosphatase and tensin homologue deleted on chromosome 10-induced putative kinase 1), PARK7 (DJ-1) and LRRK2 (leucine-rich repeat kinase 2), as well as idiopathic cases.
LRRK2 and autophagy: a common pathway for disease.
Review
New
London, United Kingdom. In Biochem Soc Trans, Oct 2012
LRRK2 (leucine-rich repeat kinase 2) is an enzyme implicated in human disease, containing kinase and GTPase functions within the same multidomain open reading frame.
A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling.
Review
New
Granada, Spain. In Biochem Soc Trans, Oct 2012
Mutations in LRRK2 (leucine-rich repeat kinase 2) represent a significant component of both sporadic and familial PD (Parkinson's disease).
An emerging role for LRRK2 in the immune system.
Review
New
Sydney, Australia. In Biochem Soc Trans, Oct 2012
Missense mutations in LRRK2 (leucine-rich repeat kinase 2) contribute significantly to autosomal dominant PD (Parkinson's disease).
Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
Review
New
Sunnyvale, United States. In Biochem Soc Trans, Oct 2012
Mutations in LRRK2 (leucine-rich repeat kinase 2) have been linked to inherited forms of PD (Parkinson's disease).
Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells.
GeneRIF
Barcelona, Spain. In Oncol Rep, 2012
LRRK2 down-regulation was associated with a clearly decreased 4E-BP1 protein in a breast cancer cell line
Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.
GeneRIF
Cambridge, United States. In Biochemistry, 2011
The increased kinase activity of the G2019S mutant is substrate-dependent.
Pathological roles of α-synuclein in neurological disorders.
Review
Impact
Athens, Greece. In Lancet Neurol, 2011
α-Synuclein also seems to be linked to other genetic forms of Parkinson's disease, such as those linked to mutations in GBA or LRRK2, possibly through common effects on autophagy and lysosomal function.
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease.
Impact
GeneRIF
Bethesda, United States. In Nat Immunol, 2011
gene deficiency conferres enhanced susceptibility to experimental colitis
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Impact
GeneRIF
Jacksonville, United States. In Lancet Neurol, 2011
The results for LRRK2 show that several rare and common genetic variants in the same gene can have independent effects on disease risk. LRRK2, and the pathway in which it functions, is important in the cause and pathogenesis of Parkinson's disease.
What genetics tells us about the causes and mechanisms of Parkinson's disease.
Review
Impact
Paris, France. In Physiol Rev, 2011
In contrast, α-synuclein accumulation in Lewy bodies defines a spectrum of disorders ranging from typical late-onset PD to PD dementia and including sporadic and autosomal dominant PD forms due to mutations in SCNA and LRRK2.
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
More papers using
LRRK2
antibodies
GeneRIF
Leuven, Belgium. In Plos One, 2010
Data show that while kinase activity of LRRK2 requires an intact ROC-GTPase domain, it is independent of GDP or GTP binding to ROC.
Purification and characterization of Rac 2. A cytosolic GTP-binding protein that regulates human neutrophil NADPH oxidase.
Supplier
In PLoS ONE, 1991
... The DR4A/3EDD anti-LRRK2-kinase domain antibody is described in reference [35] and goat polyclonal anti 14-3-3 antibody was purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ...
